This is the question everyone asks first. Not "how does it work" or "what are the side effects" — but "how much weight will I lose, and how fast?" Here is the honest, data-driven answer based on the STEP clinical trial program and real-world patient outcomes.
Month-by-Month Weight Loss on Semaglutide 2.4 mg
The following data is derived from the STEP 1 trial (n=1,961) and represents the average trajectory at the maximum approved Wegovy dose of 2.4 mg/week. Starting weight in the trial averaged approximately 232 lbs (105 kg).
| Timepoint | Avg % Lost | Example (230 lb start) | What's Happening |
|---|---|---|---|
| Month 1 | 2–3% | 225 lbs | Titration phase (0.25 mg). Appetite reduction begins. |
| Month 3 | 5–7% | 216 lbs | Reached 1.0 mg. Significant appetite suppression. |
| Month 6 | 10–12% | 205 lbs | Maintenance dose reached. Steady loss. |
| Month 9 | 12–14% | 198 lbs | Metabolic improvements accelerating. |
| Month 12 | 14.9% | 196 lbs | STEP 1 trial endpoint. ~34 lbs lost. |
| Month 16+ | 15–17% | 191 lbs | STEP 5 extension data. Continued slow loss. |
⚠️ Important Context
These are trial averages. Individual results vary based on starting weight, metabolic health, diet quality, exercise, medication adherence, and genetics. Some patients lose 20%+. Some plateau at 8–10%. Your clinician will adjust your plan based on your individual response.
Tirzepatide Comparison
For context, tirzepatide (the dual GLP-1/GIP agonist in Mounjaro/Zepbound) produces higher average weight loss at maximum dose:
- Tirzepatide 15 mg: 22.5% body weight loss at 72 weeks (SURMOUNT-1)
- Semaglutide 2.4 mg: 14.9% body weight loss at 68 weeks (STEP 1)
If maximum weight loss is your priority, explore our tirzepatide eligibility guide.
See Your Projected Results
Start your clinical intake and your clinician will provide personalized expectations based on your starting weight, metabolic profile, and health goals.
Start Your EvaluationFactors That Accelerate Results
- Protein-prioritized nutrition: 0.7–1.0 g protein per pound of goal body weight. See our nutrition guide
- Resistance training: Preserves muscle mass, increases metabolic rate, improves body composition. See our exercise protocol
- Consistent medication adherence: Weekly injections on the same day at consistent intervals
- Hydration: Minimum 64 oz daily; dehydration mimics hunger signals
- Sleep optimization: 7–9 hours nightly. Sleep deprivation increases ghrelin and reduces GLP-1 effectiveness. See our GLP-1 and sleep guide
When to Expect a Plateau
Most patients experience a weight loss plateau between months 8 and 14. This is normal and expected — it does not mean the medication has stopped working. Your body is recalibrating its metabolic setpoint. Options at this stage include dose optimization, adding structured exercise, or discussing a plateau intervention plan with your clinician.
Frequently Asked Questions
How much weight will I lose in the first month?
Typically 5–7 lbs (2–3% of body weight) during the titration phase. The first month uses the lowest dose (0.25 mg), so weight loss accelerates significantly in months 2–4 as the dose increases.
Can I lose 50 pounds on semaglutide?
If your starting weight supports it, yes. A patient starting at 280 lbs who achieves the trial average of 15% would lose approximately 42 lbs. Patients who add structured exercise and optimized nutrition frequently exceed the trial average.
Do I gain the weight back if I stop?
Without behavioral changes, approximately two-thirds of lost weight returns within a year of discontinuation. This is why we emphasize building sustainable habits during the active treatment period. Read our discontinuation guide.
Your Transformation Starts This Week
Month 1 patients are already seeing results. Where will you be 90 days from now?
Get StartedReferences
- Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
- Jastreboff, A. M., et al. (2022). Tirzepatide once weekly (SURMOUNT-1). NEJM, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038